|
Halozyme Therapeutics ، Inc. (Halo) DCF تقييم
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Halozyme Therapeutics, Inc. (HALO) Bundle
تبسيط تحليلك وتحسين الدقة مع حاسبة (HALO) DCF! مجهزة ببيانات حقيقية من Halozyme Therapeutics ، Inc. والافتراضات القابلة للتخصيص ، تتيح لك هذه الأداة التنبؤ والتقييم والتقييم (HALO) مثل المستثمر المحنك.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 267.6 | 443.3 | 660.1 | 829.3 | 1,015.3 | 1,045.5 | 1,076.5 | 1,108.4 | 1,141.3 | 1,175.2 |
| Revenue Growth, % | 0 | 65.67 | 48.91 | 25.62 | 22.44 | 2.97 | 2.97 | 2.97 | 2.97 | 2.97 |
| EBITDA | 153.0 | 259.0 | 315.5 | 451.9 | 656.5 | 590.8 | 608.3 | 626.4 | 645.0 | 664.1 |
| EBITDA, % | 57.16 | 58.43 | 47.8 | 54.5 | 64.66 | 56.51 | 56.51 | 56.51 | 56.51 | 56.51 |
| Depreciation | 3.3 | 3.0 | 49.6 | 84.9 | 81.3 | 57.8 | 59.6 | 61.3 | 63.1 | 65.0 |
| Depreciation, % | 1.23 | 0.67605 | 7.52 | 10.23 | 8.01 | 5.53 | 5.53 | 5.53 | 5.53 | 5.53 |
| EBIT | 149.7 | 256.0 | 265.9 | 367.1 | 575.2 | 533.0 | 548.8 | 565.1 | 581.8 | 599.1 |
| EBIT, % | 55.94 | 57.76 | 40.28 | 44.27 | 56.65 | 50.98 | 50.98 | 50.98 | 50.98 | 50.98 |
| Total Cash | 368.0 | 740.9 | 362.8 | 336.0 | 596.1 | 740.6 | 762.5 | 785.2 | 808.5 | 832.5 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 97.7 | 91.0 | 231.1 | 234.2 | 308.5 | 315.0 | 324.4 | 334.0 | 343.9 | 354.1 |
| Account Receivables, % | 36.52 | 20.52 | 35 | 28.24 | 30.38 | 30.13 | 30.13 | 30.13 | 30.13 | 30.13 |
| Inventories | 60.7 | 53.9 | 100.1 | 127.6 | 141.9 | 166.0 | 170.9 | 176.0 | 181.2 | 186.6 |
| Inventories, % | 22.7 | 12.16 | 15.17 | 15.39 | 13.97 | 15.88 | 15.88 | 15.88 | 15.88 | 15.88 |
| Accounts Payable | 1.9 | 1.5 | 17.7 | 11.8 | 10.2 | 12.9 | 13.3 | 13.7 | 14.1 | 14.5 |
| Accounts Payable, % | 0.72049 | 0.34761 | 2.68 | 1.42 | 1.01 | 1.24 | 1.24 | 1.24 | 1.24 | 1.24 |
| Capital Expenditure | -2.5 | -1.5 | -4.8 | -15.3 | -10.7 | -10.2 | -10.5 | -10.8 | -11.2 | -11.5 |
| Capital Expenditure, % | -0.93575 | -0.32866 | -0.72866 | -1.84 | -1.05 | -0.97817 | -0.97817 | -0.97817 | -0.97817 | -0.97817 |
| Tax Rate, % | 20.29 | 20.29 | 20.29 | 20.29 | 20.29 | 20.29 | 20.29 | 20.29 | 20.29 | 20.29 |
| EBITAT | 149.4 | 414.9 | 215.9 | 296.8 | 458.5 | 470.7 | 484.7 | 499.0 | 513.9 | 529.1 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -6.3 | 429.7 | 90.6 | 329.8 | 439.1 | 490.3 | 519.8 | 535.2 | 551.1 | 567.5 |
| WACC, % | 8.97 | 8.97 | 8.85 | 8.85 | 8.84 | 8.89 | 8.89 | 8.89 | 8.89 | 8.89 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 2,065.6 | |||||||||
| Long Term Growth Rate, % | 3.50 | |||||||||
| Free cash flow (T + 1) | 587 | |||||||||
| Terminal Value | 10,887 | |||||||||
| Present Terminal Value | 7,110 | |||||||||
| Enterprise Value | 9,176 | |||||||||
| Net Debt | 1,390 | |||||||||
| Equity Value | 7,786 | |||||||||
| Diluted Shares Outstanding, MM | 129 | |||||||||
| Equity Value Per Share | 60.16 |
What You Will Gain
- Pre-Populated Financial Model: Halozyme's actual data facilitates accurate DCF valuation.
- Comprehensive Forecast Control: Modify revenue growth, profit margins, WACC, and other essential factors.
- Immediate Calculations: Automatic updates provide real-time results as you make adjustments.
- Investor-Ready Template: A polished Excel file crafted for professional-level valuation.
- Customizable and Repeatable: Designed for adaptability, allowing for repeated use in detailed forecasts.
Key Features
- Comprehensive Financial Data: Gain access to precise historical figures and future forecasts for Halozyme Therapeutics, Inc. (HALO).
- Adjustable Projection Parameters: Modify highlighted fields such as WACC, growth rates, and profit margins to fit your analysis.
- Automated Financial Calculations: Instant updates for DCF, Net Present Value (NPV), and cash flow assessments.
- User-Friendly Visualization: Intuitive charts and summaries to clearly present your valuation findings.
- Designed for All Skill Levels: A straightforward layout tailored for investors, financial officers, and consultants alike.
How It Works
- 1. Access the Template: Download and open the Excel file containing Halozyme Therapeutics, Inc.'s preloaded data.
- 2. Adjust Parameters: Modify key inputs such as growth rates, WACC, and capital expenditures.
- 3. View Results in Real-Time: The DCF model automatically calculates intrinsic value and NPV.
- 4. Explore Scenarios: Evaluate various forecasts to analyze different valuation results.
- 5. Present with Assurance: Share professional valuation insights to back your strategic decisions.
Why Choose This Calculator for Halozyme Therapeutics, Inc. (HALO)?
- Accuracy: Utilizes real Halozyme financial data for precise calculations.
- Flexibility: Allows users to easily adjust and experiment with various inputs.
- Time-Saving: Eliminate the complexities of constructing a DCF model from the ground up.
- Professional-Grade: Crafted with the expertise and precision expected at the CFO level.
- User-Friendly: Intuitive interface suitable for users with varying levels of financial modeling expertise.
Who Should Use This Product?
- Investors: Accurately assess Halozyme Therapeutics’ fair value before making investment decisions.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to Halozyme (HALO).
- Consultants: Easily customize the template for valuation reports tailored to Halozyme (HALO) clients.
- Entrepreneurs: Gain insights into the financial modeling practices of leading biotech companies like Halozyme (HALO).
- Educators: Employ it as a teaching resource to illustrate valuation methodologies in the biotech sector.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Halozyme Therapeutics historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Halozyme Therapeutics, Inc. (HALO).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.